Vaginal Microbicides

Adolescent Medicine Clinics

Volumn 17, Issue 3, 2006, Pages 673-685

  O'Brien, Rebecca Flynn ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS USED INTRAVAGINALLY; ANTIVIRUS AGENT; SPERMICIDAL AGENT; TOPICAL ANTIINFECTIVE AGENT;

FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW;

ANTI-INFECTIVE AGENTS, LOCAL; ANTIVIRAL AGENTS; FEMALE; HIV INFECTIONS; HUMANS; SPERMATOCIDAL AGENTS; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 33749500568     PISSN: 15473368     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.admecli.2006.06.004     Document Type: Review

References (36)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS epidemic update: December 2005. Available at: http://www.unaids.org/epi/2005. Accessed March 31, 2006.
2. Ojikutu B.O., and Stone V.E. Women, inequality and the burden of HIV. N Engl J Med 352 (2005) 649-652
3. Padian N.S., Shiboski S.C., Glass S.O., et al. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. Am J Epidemiol 146 (1997) 350-357
4. Madan R.P., Keller M.J., and Herold B.C. Prioritizing prevention of HIV and sexually transmitted infections: first generation vaginal microbicides. Curr Opin Infect Dis 19 (2006) 49-54
5. Galvin S.R., and Cohen M.S. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2 (2004) 33-42
6. Ghys P.D., Fransen K., Diallo M.O., et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS 11 (1997) F85-F93
7. Cohen M.S., Hoffman I.F., Royce R.A., et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV. Lancet 349 (1997) 1868-1873
8. McClelland R.S., Wang C.C., Mandaliya K., et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 15 (2001) 105-110
9. Dhawan D., and Mayer K.H. Microbicides to prevent HIV transmission: overcoming obstacles to chemical barrier protection. J Infect Dis 193 (2006) 36-44
10. Fichorova R.N., Tucker L.D., and Anderson D.J. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 184 (2001) 418-428
11. Richardson B.A. Nonoxynol-9 as a vaginal microbicide for prevention of sexually transmitted infections: it's time to move on. JAMA 287 (2002) 1171-1172
12. Alliance for Microbicide Development. Microbicide clinical trials (March 2006). Summary: Microbicide candidate compounds and products in development. Available at: http://www.microbicide.org/publications. Accessed March 26, 2006.
13. Barnhart K.T., Pretorius E.S., Shaunik A., et al. Vaginal distribution of two volumes of the novel microbicide gel cellulose sulfate (2.5 and 3.5 ml). Contraception 72 (2005) 65-70
14. Pretorius E.S., Timbers K., Malamud D., et al. Magnetic resonance imaging to determine the distribution of vaginal gel: before, during and after both real and simulated intercourse. Contraception 66 (2002) 443-451
15. Barnhart K.T., Pretorius E.S., Timbers K., et al. Distribution of 3.5 ml (1.0%) C31G vaginal gel using magnetic resonance imaging. Contraception 71 (2005) 357-361
16. Mauck C.K., Weiner D.H., Creinin M.D., et al. A randomized phase I vaginal safety study of three concentrations of C31G vs. Extra Strength Gynol II. Contraception 70 (2004) 233-240
17. Cellegy Pharmaceuticals, Inc. Saavy (1% C31G vaginal gel) Product Overview. Available at: http://www.cellegy.com/products/saavy.html. Accessed April 2, 2006.
18. van de Wijgert J., Fullem A., Kelly C., et al. Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr 26 (2001) 21-27
19. Mayer K.H., Peipert J., Fleming T., et al. The safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States. Clin Infect Dis 32 (2001) 476-482
20. Khanna K.V., Whaley K.J., Zeitlin L., et al. Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J Clin Invest 109 (2002) 205-211
21. Zeitlin L., Hoen T.E., Achilles S.L., et al. Test of BufferGel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis 28 (2001) 417-423
22. Patton D.L., Sweeney T.C., Cummings P.K., et al. Safety and efficacy evaluations for vaginal and rectal use of BufferGel in the macaque model. Sex Transm Dis 31 (2004) 290-296
23. Garg S., Anderson R.A., Chany C.J., et al. Properties of a new acid-buffering bioadhesive vaginal formulation (ACIDFORM). Contraception 64 (2001) 67-75
24. Amaral E., Faundes A., Zaneveld L., et al. Study of the vaginal tolerance to ACIDFORM an acid buffering bioadhesive gel. Contraception 60 (1999) 361-366
25. Perotti M.E., Pirovano A., and Phillips D.M. Carrageenan formulation prevents macrophage trafficking from vagina: implications for microbicide development. Biol Reprod 69 (2003) 933-939
26. Carlucci M.J., Scolaro L.A., Noseda M.D., et al. Protective effect of a natural carrageenan on genital herpes simplex virus infection in mice. Antiviral Res 64 (2004) 137-141
27. Maguire R.A., Berman N., and Phillips D.M. Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex Transm Dis 28 (2001) 259-265
28. Mauck C., Weiner D.H., Ballagh S., et al. Single and multiple exposure tolerance study of cellulose sulfate gel: a phase I safety and colposcopic study. Contraception 64 (2001) 383-391
29. Mayer K.H., Karim S.A., Kelly C., et al. Safety and tolerability of vaginal Pro 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS 17 (2003) 321-329
30. Keller M.J., Zerhouni-Layachi B., Cheshenko N., et al. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal applications: a double-blind placebo-controlled trial. J Infect Dis 193 (2006) 27-35
31. Cohen J. HIV/AIDS prevention cocktails: combining tools to stop HIV's spread. Science 309 (2005) 1002-1005
32. Van Herrewege Y., Michiels J., Van Roey J., et al. In vitro evaluation of non-nucleoside reverse transcriptase inhibitors UC-781 and TMC 120-R147681 as HIV microbicides. Antimicrob Agent Chemother 48 (2004) 337-339
33. Shankar P., Manjunath N., and Lieberman J. The prospect of silencing disease using RNA interference. JAMA 293 (2005) 1367-1372
34. Johnson D.C. Silencing herpes simplex virus with a vaginal microbicide. N Engl J Med 354 (2006) 970-971
35. Paliser D., Chowdhury D., Wang Q.-Y., et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439 (2006) 89-94
36. Wald A., and Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis 185 (2002) 45-52